ATIVAN (lorazepam)
ATIVAN is indicated for the treatment of Status Epilepticus; Anxiety.
How ATIVAN Works
The specific mechanism of action for this medication is not specified in the provided FDA labeling. It is categorized within the benzodiazepine established pharmacologic class. The drug is utilized to produce therapeutic effects including sedation, the relief of anxiety, and a decreased ability to recall surgical events.
Details
- Status
- Prescription
- First Approved
- 1977-09-30
- Routes
- ORAL, INJECTION
- Dosage Forms
- TABLET, INJECTABLE
ATIVAN Approval History
What ATIVAN Treats
2 indicationsATIVAN is approved for 2 conditions since its original approval in 1977. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Status Epilepticus
- Anxiety
ATIVAN Boxed Warning
RISKS FROM CONCOMITANT USE WITH OPIOIDS ; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PREC...
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS ; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including ATIVAN Injection, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing ATIVAN Injection and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS ) . The continued use of benzodiazepines for several days to weeks may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although ATIVAN Injection is indicated only for intermittent use (see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION ), if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of ATIVAN Injection may precipitate acute withdrawal reactions, which can be life-threatening. For patients using ATIVAN Injection more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue ATIVAN Injection (see WARNINGS ).
ATIVAN Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ATIVAN
3 of 14FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
36 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05662228 | 22-1992 | Ph 2 | active not recruiting | Therapies for Down Syndrome Regression Disorder |
| NCT01949662 results posted | 2013-0345 NCI-2013-02351, 1R21CA186000-01A1 | Ph 2 | active not recruiting | Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer |
| NCT03743649 | 2018-0706 NCI-2018-02438, 2018-0706 | Ph 2, Ph 3 | active not recruiting | Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care |
| NCT06004115 | 2022-009 R01MH132565 | Ph 4 | recruiting | Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression |
| NCT06799494 | STUDY00008623 | Ph 4 | recruiting | HPV Vaccine Reduced Dose |
| NCT04240626 | 1452523 | Ph 4 | active not recruiting | Multimodal Analgesia Effect on Post Surgical Patient |
| NCT05599126 | 2021-TX-002 | Ph 4 | recruiting | A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems |
| NCT04715230 Meth-OD results posted | M200C-2101 U01DA053043 | Ph 2 | terminated | Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose |
| NCT01441843 results posted | NL3253507810 | Ph 4 | completed | Resistance Under the Microscope |
| NCT03090620 TAAT results posted | 16-1730 | Ph 4 | completed | Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome |
| NCT00624780 results posted | A0081147 | Ph 4 | completed | Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder |
| NCT03021018 results posted | EP0087 | Ph 2 | completed | A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting |
| NCT03756038 results posted | PRO18090064 | Ph 2 | terminated | Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care |
| NCT01889602 results posted | CPDEC | Ph 4 | completed | Characterizing and Predicting Drug Effects on Cognition |
| NCT03788889 PKAT | 18-94 | Ph 4 | withdrawn | Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine |
| NCT01330459 results posted | OHSU FAMPLAN 6734 | Ph 4 | completed | Hydrocodone For Pain Control in First Trimester Surgical Abortion |
| NCT01275144 results posted | 12596 H9P-EW-LNCG | Ph 1 | completed | A Study of the Effect of LY2216684 on Lorazepam |
| NCT02239380 results posted | B3541002 2017-000125-13 | Ph 3 | completed | Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan |
| NCT01870024 LORACLOFT | P110123 2012-003795-39 | Ph 3 | completed | Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus |
| NCT03180632 Endo-Lora | JP2017 | Ph 2 | completed | Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy: |
| NCT02407704 MEDEX results posted | MH090333-04 PRO13110090, MH090333 | Ph 4 | completed | A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise |
| NCT02134366 | EPC-1 | Ph 3 | terminated | Clobazam Use in Epilepsia Partialis Continua - Pilot Study |
| NCT02564029 results posted | B7431005 | Ph 2 | completed | PF-06372865 in Subjects With Photosensitive Epilepsy |
| NCT02374567 GAP | GAP-2014 | Ph 3 | terminated | Pharmacovigilance in Gerontopsychiatric Patients |
| NCT01780519 | 12-006469 | Ph 1 | completed | The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms |
| NCT02147548 | ETILANCE - ETI 175 | Ph 3 | completed | Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly |
| NCT02462109 CINS | HS 1330 | Ph 1 | completed | Catatonia in Nodding Syndrome and Lorazepam Treatment |
| NCT01901003 PremedX | 2011-005171-16 2011-32 | Ph 3 | completed | Sedative Premedication: Efficacy On Patient Experience |
| NCT01994668 | B3541001 | Ph 1 | completed | Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects |
| NCT01827293 | SB-067 | Ph 3 | completed | Promethazine vs. Lorazepam for Treatment of Vertigo |
| NCT00736931 | N01297 | Ph 1 | completed | Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam |
| NCT00720421 | D1140C00003 EudractCT 2008-001757-17 | Ph 1 | completed | A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator. |
| NCT00807937 results posted | D1140C00014 | Ph 2 | completed | Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325 |
| NCT00902772 | D1140C00008 | Ph 1 | completed | Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users |
| NCT00750802 | D0850C00014 Eudract # 2008-001757-17 | Ph 1 | completed | A Sedation/Cognition/EEG Study Using AZD6280 and Comparator |
| NCT00735527 INLOR | INLOR | Ph 3 | completed | Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ATIVAN FDA Label Details
Indications & Usage
FDA Label (PDF)ATIVAN is indicated for the treatment of Status Epilepticus; Anxiety.
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS ; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients...
Track ATIVAN with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.